Corbus Pharmaceuticals
CRBP
28 hedge funds and large institutions have $5.8M invested in Corbus Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 4 closing their positions.
5,500% more call options, than puts
Call options by funds: $280K | Put options by funds: $5K
10% more capital invested
Capital invested by funds: $5.26M → $5.8M (+$537K)
0.59% less ownership
Funds ownership: 17.36% → 16.77% (-0.59%)
7% less funds holding
Funds holding: 30 → 28 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$161K |
| 2 |
BlackRock
New York
|
+$88.2K |
| 3 |
DWA
Dorsey Wright & Associates
Pasadena,
California
|
+$23K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$13.6K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$73K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$40.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.49K |
| 4 |
Morgan Stanley
New York
|
-$2.93K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IA
26
IFP Advisors
Tampa,
Florida
| $24 | -$899 | -100 | -97% |
|
27
Bank of America
Charlotte,
North Carolina
| $8 | – | – | – |
|
|
SSB
28
Sandy Spring Bank
Olney,
Maryland
| $8 | – | – | – |
|
|
VF
29
Virtu Financial
New York
| – | -$73K | -10,077 | Closed |
|
|
CG
30
Cutler Group
San Francisco,
California
| – | -$2K | -353 | Closed |
|
|
AWM
31
Accel Wealth Management
Waverly,
Iowa
| – | -$334 | -46 | Closed |
|
|
BAM
32
Belpointe Asset Management
Reno,
Nevada
| – | -$160 | -22 | Closed |
|
CRBP Hedge Fund Activity: Q2 2023 in Review
28 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q2 2023, worth a combined $5.8M — up 10% from $5.26M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CRBP and 2 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 4 added.
The largest buyer was Dimensional Fund Advisors, adding an estimated $161K. The largest seller was Virtu Financial, exiting entirely with an estimated $73K sold.
- 28 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q2 2023, down from 30 in Q1 2023.
- Funds reported $5.8M of Corbus Pharmaceuticals stock for Q2 2023, up 10% quarter-over-quarter.
- 2 funds opened new Corbus Pharmaceuticals positions in Q2 2023 and 4 closed out, a net change of -2 holders.
- The largest Corbus Pharmaceuticals buyer in Q2 2023 was Dimensional Fund Advisors, an estimated $161K added.
- The largest Corbus Pharmaceuticals seller in Q2 2023 was Virtu Financial, an estimated $73K sold.
Based on aggregated 13F filings for Q2 2023.